IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Regeneron Pharmaceuticals, Inc. v Kymab Limited [2019] APO 36
Patent Application: 2011266843
Title:Animal models and therapeutic molecules
Patent Applicant: Kymab Limited
Opponent: Regeneron Pharmaceuticals, Inc.
Delegate: Sophina Calanni
Decision Date: 31 July 2019
Hearing Date: 14 September 2018, in Melbourne
Catchwords: PATENTS - section 59 opposition to grant of a patent – grounds of novelty, inventive step, clarity and fair basis – whether the claims suffer from parameteritis – whether the prior disclosure is enabled – whether the citation is publicly available – whether two citations may be considered a single source of information – whether the claimed product is an inevitable consequence of an earlier disclosed method – opposition unsuccessful on all grounds
Representation: Counsel for the applicant: Mr Tom Cordiner
Patent attorney for the applicant: Amanda Stark and Gavin Adkins, Griffith Hack
Counsel for the opponent: Mr Ben Fitzpatrick
Patent attorney for the opponent: Dr Prue Cowin and Dr Ian Rourke, FB Rice
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2011266843
Title:Animal models and therapeutic molecules
Patent Applicant: Kymab Limited
Date of Decision: 31 July 2019
DECISION
The Opposition is unsuccessful.
Costs awarded against Regeneron Pharmaceuticals, according to Schedule 8 of the Regulations.
REASONS FOR DECISION
Background
1. Patent application 2011266843 (the application) was filed by Kymab Limited (Kymab) on 7 January 2011 under the provisions of the Patent Cooperation Treaty. The application claims priority from two priority documents, US 61/355,666 and PCT/GB2010/051122, with an earliest priority date of 17 June 2010.
2. The application was examined and advertised accepted on 30 April 2015. Regeneron Pharmaceuticals, Inc. (Regeneron) filed a notice of opposition under section 59 of the Patents Act 1990 (the Act) on 30 July 2015.
3. The statement of grounds and particulars (SG&P) was filed on 30 October 2015. Throughout the opposition process, the SG&P was amended several times, with the final SG&P filed 31 January 2018 and allowed on 15 February 2018.
4. Kymab proposed amendments to the specification, specifically the claims, under section 104 on 3 August 2016, 7 September 2016, 25 October 2016. These amendments were successfully opposed by Regeneron[1]. Kymab subsequently filed further amendments to the claims on 6 September 2017. These amendments were allowed unopposed on Jan 2018. This decision is in relation to the specification as amended.
Evidence
The parties relied upon evidence by several declarants as set out in the table below.
Evidence Declarant Date of Declaration Reference Exhibits In support Dr Ian J. Rourke 20 January 2016 Rourke IJR-1 to IJR-49 Dr Chris C. Goodnow 29 January 2016 Goodnow #1 CCG-1 to CCG-2 Dr Mark W. Sleeman 29 January 2016 Sleeman #1 MWS-1 to MWS-2 Dr Lynn E. Macdonald 26 January 2016 Macdonald #1 LEM-1 to LEM-4 In answer Dr Victor Tybulewicz 29 April 2016 Tybulewicz #1 VT-1 to VT-4 Dr Marcus van Dijk 30 April 2016 van Dijk #1 MVD-1 to MVD-5 In reply Dr Chris C. Goodnow 4 July 2016 Goodnow #2
Keep reading for free
Create a free CaseChat account to read Regeneron Pharmaceuticals, Inc. v Kymab Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] APO 36
- Decision Date
CaseChat Overview and Summary
The court found that the opposition was unsuccessful on all grounds. It held that the claims did not suffer from parameteritis as they were not overly broad or undefined. The court also found that the prior disclosure was enabled and that the citation was publicly available. Furthermore, the court ruled that two citations could be considered a single source of information if they were authored by the same entity and published contemporaneously. Lastly, the court determined that the claimed product was not an inevitable consequence of an earlier disclosed method as there were significant differences between the two.
In light of the findings, the opposition was dismissed, and the patent was granted to Kymab Limited. The court's decision emphasised the importance of clarity and specificity in patent claims and highlighted the need for prior art to be enabled and publicly available. Additionally, the decision clarified the circumstances in which two citations may be considered a single source of information. The case serves as a useful reminder to patent applicants and opponents of the requirements for a valid patent and the importance of thorough prior art searches.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.